Yale University
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Yale University sits in the top decile of US sponsors by registered trial count (#13 of 15,742 sponsors by registered trial count).
Yale University: 1,492 sponsored US clinical trials, 254 recruiting.
Yale University sponsors 1,492 registered US clinical trials on ClinicalTrials.gov, 254 of them currently recruiting, and 1,005 completed. 99 of these trials are in Phase 3-4 (later-stage) and 579 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Opioid Use Disorder, with 19 trials.
Top-decile sponsor footprint
Yale University ranks in the top decile of sponsors by registered trial count (#13 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,005 of 1,138 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,492 total, page 17 of 30
Carotid Doppler Ultrasound for the Measurement of Intravascular Volume Status
NCT02907931
Topical Tofacitinib for the Treatment of Alopecia Areata and Its Variants
NCT02812342
A Unified Intervention for Young Gay and Bisexual Men's Minority Stress, Mental Health, and HIV Risk
NCT02929069
Working With HIV Clinics to Adopt Addiction Treatments Using Implementation Facilitation
NCT02907944
A Study Comparing the Quality of Life of Patients in the Treatment of Eczema by Pediatric Generalists and Specialists
NCT02916888
Prehospital Use of Ultrasound in Undifferentiated Shortness of Breath
NCT02638649
A Randomized Trial of a Combination of Nintedanib/Placebo in Combination With Induction Chemotherapy for Patients With Refractory or First Relapse Acute Myeloid Leukemia
NCT02665143
Validation and Refinement of Noninvasive Diagnostic Biomarkers for Endometriosis, The ENDOmarker Protocol
NCT03161704
Impact of Immediate Point-of-Care Ultrasound on Patients With Cardiopulmonary Symptoms in the Emergency Department
NCT02861508
Bright 1 Bodies Weight Management Program
NCT02768987
Treatment of High-Grade Pre-Neoplastic Cervical Lesions (CIN 2/3)
NCT02864147
Shave Margins vs. Standard Partial Mastectomy in Breast Cancer Patients
NCT02772731
Prevention of Delirium in Inpatients Utilizing Melatonin
NCT02654314
Does CERC-501 Attenuate Stress-precipitated Smoking Lapse?
NCT02800928
Development of Patient Centered Virtual Multimedia Interactive Informed Consent Tool to Improve Patient Comprehension and Consent
NCT02537886
Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer (NSCLC)
NCT02681549
Functional Magnetic Resonance Imaging of N-acetylcysteine in Cocaine Dependence
NCT02994875
SPECT/CT Imaging of Skeletal Muscle Perfusion
NCT02791204
Investigating the Central and Peripheral Mechanisms by Which Glucocorticoids Affect Hunger
NCT02722200
Testing the Interactive Effects of Delta-9-Tetrahydrocannabinol and Pregnenolone: Sub-Study I
NCT02811939
Progesterone Augmentation of Nicotine Replacement Therapy Study
NCT02685072
Bridge Occlusion Balloon in Lead Extraction Procedure
NCT02714153
CBT for Anxiety in Children With Autism
NCT02725619
Study to Investigate Adipocyte Cell and Lipid Turnover in Obese Adolescents
NCT02395003
Insomnia Self-Management in Heart Failure
NCT02660385
A Mail and Video-based Weight Loss Trial in Breast Cancer Survivors
NCT02681965
Examining the Impact of Sirolimus on Ketamine's Antidepressant Effects
NCT02487485
A Naturalistic Study of Adolescents and Young Adults in Treatment for Opioid Dependence
NCT02718352
A Pilot Trial of Curcumin Effects on Cognition in Schizophrenia
NCT02476708
Trial Comparing Early Laparoscopic Enterolysis Versus Nonoperative Management for High-grade SBO
NCT02692638
Physical Activity and Glycemic Control in Adolescents
NCT02674828
Investigation Into the Effects of Blood Glucose Levels Upon Eating Behavior in Lean and Obese Non-diabetic and Diabetic Subjects
NCT02673203
Cannabidiol Treatment in Patients With Early Psychosis
NCT02504151
Indoor Air Pollution and Children With Asthma: An Intervention Trial
NCT02258893
Personalized Intervention Program: Tobacco Treatment for Patients at Risk for Lung Cancer (PIP)
NCT02658032
Effect of Canagliflozin in T1DM (Type 1 Diabetes Melitus) After Interruption of Continuous Subcutaneous Insulin Infusion
NCT02673138
Tracking Intervention Effects With Eye Tracking
NCT02856061
Assessing the Role of a Fermented Soy Extract in Inflammation and the Human Microbiome
NCT02656056
Sleep, Coping and Executive Functioning in Youth With Type 1 Diabetes
NCT02908555
Males, Antioxidants, and Infertility Trial
NCT02421887
Novel and Scalable Internet Supplemented Weight Loss Treatment in Primary Care
NCT02578199
Intensive 7-day Treatment for PTSD Combining Ketamine With Exposure Therapy
NCT02727998
Perioperative Blood Pressures and Chronic Hypertension
NCT02136810
Associations of Socioeconomic Adversity and Sleep With Allostatic Load Among Toddlers
NCT03419871
Pharmacokinetics of Doxorubicin in cTACE of Liver Cancer
NCT02753881
Investigating the Interactions of AZD0530 With Alcohol in Social Drinkers
NCT02732587
Automated Recovery Line for Medication Assisted Treatment
NCT02124980
Neoadjuvant MEDI4736 Concomitant With Weekly Nab-paclitaxel and Dose-dense AC for Stage I-III Triple Negative Breast Cancer
NCT02489448
Multimodal Neuroimaging of Stress and Reward Cues to Assess Alcoholism Risk and Relapse
NCT02616094
Single Agent Versus Combination Chemotherapy to Treat High-risk Elderly With Non-small Cell Lung Cancer
NCT02590003
What is open in the Yale University pipeline
254 recruiting of 1,492 indexed (17% open); 1,005 completed (67%).
Phase mix: 99 late (III/IV) vs 579 early (I/II) (early-phase heavy).
Top condition: Opioid Use Disorder (19 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Yale University: open-pipeline peers nationwide
Peers matched on 1,492 registered trials and 17% open enrollment, not the therapeutic-area sidebar.
Yale University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,492 trials (± recruiting share)
- Washington University School of Medicine · 1,502 trials · 14% recruiting
- Johns Hopkins University · 1,448 trials · 17% recruiting
- University of Pennsylvania · 1,423 trials · 14% recruiting
- Novartis Pharmaceuticals · 1,375 trials · 8% recruiting
Sponsors near 17% open enrollment (± trial volume)
- NYU Langone Health · 17% recruiting · 1,164 trials
- CSL Behring · 17% recruiting · 71 trials
- Penn State University · 17% recruiting · 219 trials
- University of Hawaii · 17% recruiting · 77 trials
Related
What to do with this Yale University page
1,492 registered trials is a research-attention snapshot, not an endorsement of Yale University or any single study.
- 254 of Yale University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Opioid Use Disorder is the condition Yale University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Opioid Use Disorder trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Yale University pipeline card: 1,492 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.